FDA grants approval to Samsung Bioepis’ Ospomyv and Xbryk, expanding access to biosimilar treatments for osteoporosis and cancer-related bone loss
The U.S. Food and Drug Administration (FDA) has approved Ospomyv™ and Xbryk™, two biosimilars developed by Samsung Bioepis Co., Ltd., referencing Prolia and Xgeva, respectively. ... Read More
Amgen and UCB resubmit BLA for EVENITY to transform osteoporosis treatment in postmenopausal women
Amgen, in collaboration with UCB, has announced the resubmission of the biologics license application (BLA) for their osteoporosis drug candidate, EVENITY (romosozumab), to the US ... Read More